UPC Universe Pharmaceuticals INC

$1.47 +2.08%

Data as of Nov 3, 2026 close

Healthcare · Pharmaceutical Preparations

Universe Pharmaceuticals INC (UPC) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $828107. Shares last traded at $1.47. Net profit margin is -20.6%, below the peer median of -7.4%. Revenue declined 22.4% year over year.

Market Cap

$1M

Shares Out

563,338

EPS (TTM)

-$8.06

P/E (TTM)*

—

P/S Ratio

0.00

P/B Ratio

0.00

Dividend / Share

—

Dividend Yield

—

52-Week High

—

52-Week Low

—

Volume (venue)

6,535

Avg Vol (3m, venue)

3,991.54

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

-37.45%

-68.66%

-75.08%

—

YTD

—

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. UPC split history →

Technicals

RSI (14)

24.27

SMA (50)

$4.10

SMA (200)

—

Price vs SMA50

-64.18%

Price vs SMA200

—

ATR (14)

$0.40

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$17.9B

Net Income

-$3.7B

Gross Margin

35.3%

Operating Margin

-16.3%

Net Margin

-20.6%

Return on Equity

-6.5%

Return on Assets

-5.3%

Current Ratio

4.07

Debt / Equity

0.23

Revenue Growth (YoY)

-22.4%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2025-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Pharmaceutical Preparations peers

UPC vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of Nov 3, 2026 close

P/S vs peers

0.00 / 7.47 med

-100% discount

Net margin vs peers

-20.6% / -7.4% med

below median

1–14 of 14


LLY	Lilly (Eli)	$1.33T	48.07	15.33	31.9%	-0.17%
JNJ	Johnson & Johnson	$640.8B	39.81	6.45	16.2%	-1.62%
ONC	Beone Medicines Ltd.	$524.6B	800.05	85.59	10.7%	-1.72%
ABBV	AbbVie	$505.3B	48.86	7.66	15.7%	-1.00%
MRK	Merck	$357.0B	112.50	5.36	4.8%	-2.57%
ABT	Abbott Laboratories	$190.6B	30.37	4.22	13.9%	-0.77%
PFE	Pfizer	$170.9B	42.37	2.69	6.3%	-2.38%
VRTX	Vertex Pharmaceuticals	$134.7B	33.87	10.40	30.7%	-4.18%
BMY	Bristol Myers Squibb	$126.1B	13.65	2.52	18.5%	-2.09%
REGN	Regeneron Pharmaceuticals	$100.7B	20.91	5.96	28.5%	+1.30%
TEVA	Teva Pharmaceutical Industries Ltd	$48.9B	96.62	2.84	2.9%	+3.00%
ZTS	Zoetis	$34.3B	13.11	3.60	27.5%	-0.18%
RPRX	Royalty Pharma Plc	$29.5B	36.25	11.65	32.1%	-0.26%
ROIV	Roivant Sciences Ltd.	$26.0B	—	3458.17	—	+0.47%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.